|
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
• Significant correlation exists between radiological parameters such as volumetric and ADC values and major genomic profiles such as IDH mutation and ATRX loss status • Radiological parameters such as the ADC value were feasible predictors of glioblastoma patients' prognosis • Imaging features can predict major genomic profiles of the tumours and the prognosis of glioblastoma patients.
|
29721688 |
2018 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
• Significant correlation exists between radiological parameters such as volumetric and ADC values and major genomic profiles such as IDH mutation and ATRX loss status • Radiological parameters such as the ADC value were feasible predictors of glioblastoma patients' prognosis • Imaging features can predict major genomic profiles of the tumours and the prognosis of glioblastoma patients.
|
29721688 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
• Significant correlation exists between radiological parameters such as volumetric and ADC values and major genomic profiles such as IDH mutation and ATRX loss status • Radiological parameters such as the ADC value were feasible predictors of glioblastoma patients' prognosis • Imaging features can predict major genomic profiles of the tumours and the prognosis of glioblastoma patients.
|
29721688 |
2018 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
• Significant correlation exists between radiological parameters such as volumetric and ADC values and major genomic profiles such as IDH mutation and ATRX loss status • Radiological parameters such as the ADC value were feasible predictors of glioblastoma patients' prognosis • Imaging features can predict major genomic profiles of the tumours and the prognosis of glioblastoma patients.
|
29721688 |
2018 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
• APT signals were significantly higher in IDH-wild type compared to IDH-mutant high-grade glioma.
|
31175415 |
2019 |
|
High grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
• APT signals were significantly higher in IDH-wild type compared to IDH-mutant high-grade glioma.
|
31175415 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
|
27568035 |
2016 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Young patients with IDH wild type astrocytomas and glioblastoma had better outcomes than reported historical controls.
|
31371189 |
2019 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Without exception, all were R132C (CGT-->TGT), which in sporadic astrocytomas accounts for <5% of IDH1 mutations.
|
19340432 |
2009 |
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Within the molecularly-defined IDH wild-type GBM cohort, younger patients had significantly more mutations in PDGFRA, PTPN11, SMARCA4, BRAF and TP53.
|
27579614 |
2016 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Within the molecularly-defined IDH wild-type GBM cohort, younger patients had significantly more mutations in PDGFRA, PTPN11, SMARCA4, BRAF and TP53.
|
27579614 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Within pGBIV, the rare subtype of IDH1 mutant tumors shared expression profiles with IDH1 mutant sGBIV and was associated with longer overall survival compared with IDH1 wild-type tumors.
|
20473936 |
2011 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
With the advent of molecular genetics, molecular diagnostic testing has been added to histological evaluation in the armamentarium of the pathologist, and the recent World Health Organization (WHO) Classification of Tumors of the Central Nervous System encourages testing for isocitrate dehydrogenase (IDH) gene status in the classification of diffuse astrocytic gliomas.
|
29548048 |
2018 |
|
Central Nervous System Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
With the advent of molecular genetics, molecular diagnostic testing has been added to histological evaluation in the armamentarium of the pathologist, and the recent World Health Organization (WHO) Classification of Tumors of the Central Nervous System encourages testing for isocitrate dehydrogenase (IDH) gene status in the classification of diffuse astrocytic gliomas.
|
29548048 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
With median follow-up of 8.3 months for 174 adults with IDH1-mutated R/R AML treated with 500 mg ivosidenib daily, the CR + CRh rate was 33% [95% confidence interval (CI), 26-40], median duration of response was 8.2 (95% CI, 5.6-12) months, and conversion from TD to TI occurred in 37% of patients.
|
30692099 |
2019 |
|
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With median follow-up of 8.3 months for 174 adults with IDH1-mutated R/R AML treated with 500 mg ivosidenib daily, the CR + CRh rate was 33% [95% confidence interval (CI), 26-40], median duration of response was 8.2 (95% CI, 5.6-12) months, and conversion from TD to TI occurred in 37% of patients.
|
30692099 |
2019 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With a long course of slowly progressing, this was a rare case of secondary glioblastoma with the absence of isocitrate dehydrogenase 1 (IDH1) gene mutation.
|
31555204 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
With a case control study in 285 gliomas, 316 healthy controls, 380 systemic cancers, 31 other CNS-tumors, and 120 IDH-mutant cartilaginous tumors, we identified that the association was specific to IDH-mutant gliomas.
|
27282637 |
2016 |
|
Pilocytic Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Wild-type (WT) IDH1 was detected in cases with a World Health Organization (WHO) grade I astrocytoma.
|
23934769 |
2014 |
|
Grade I Astrocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Wild-type (WT) IDH1 was detected in cases with a World Health Organization (WHO) grade I astrocytoma.
|
23934769 |
2014 |
|
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
|
30738431 |
2019 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
|
30738431 |
2019 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
|
30738431 |
2019 |
|
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
|
30738431 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Whole-genome sequencing identified a total of 55 coding mutations (range 8-32 mutations per tumor), including known abnormalities in IDH1, IDH2, CIC and FUBP1.
|
25694352 |
2015 |